Article
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.
Nature communications - 4 Sept 2017
Jacobsen Kirstine, Bertran-Alamillo Jordi, Molina Miguel Angel, Teixidó Cristina, Karachaliou Niki, Pedersen Martin Haar, Castellví Josep, Garzón Mónica, Codony-Servat Carles, Codony-Servat Jordi, Giménez-Capitán Ana, Drozdowskyj Ana, Viteri Santiago, Larsen Martin R, Lassen Ulrik, Felip Enriqueta, Bivona Trever G, Ditzel Henrik J, Rosell Rafael
Abstract excerpt
Non-small-cell lung cancer patients with activating epidermal growth factor receptor (EGFR) mutations typically benefit from EGFR tyrosine kinase inhibitor treatment. However, virtually all patients succumb to acquired EGFR tyrosine kinase inhibitor resistance that occurs via diverse mechanisms. The diversity and unpredictability of EGFR tyrosine kinase inhibitor resistance mechanisms presents a challenge for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.